BEVERLY, Mass., Nov. 2, 2009 (GLOBE NEWSWIRE) -- Cellceutix Corporation (OTCBB:CTIX), a bio-pharmaceutical company that develops small molecules to treat cancer and inflammatory disease, today announced that is has concluded an agreement with Toxikon Corporation of Bedford, Massachusetts, to conduct the remaining preclinical studies required for an Investigational New Drug (IND) filing for its cancer drug Kevetrin(TM). The terms of the agreement were not disclosed. The studies covered by the agreement are designed to confirm that Kevetrin meets FDA safety requirements for studies in humans.
